We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid DNA Flow Technology Platform Detects Tick-Borne Bacterial Pathogens

By LabMedica International staff writers
Posted on 13 Nov 2019
Ticks are the most important vectors for infectious diseases in the northern hemisphere and second only after mosquitos worldwide. More...
As a result, there is an increasing public health interest in tick-borne pathogens.

Ticks can transmit diseases such as Lyme disease, human granulocytic anaplasmosis, and spotted fever rickettsioses, among others. Therefore, there is a growing need to develop better and faster diagnostic tools that can detect zoonotic human pathogens in clinical samples.

Medical Infectious Disease Scientists from Rutgers University (New Brunswick, NJ, USA) and their international colleagues collected samples from 212 patients who presented a broad range of clinical signs/symptoms consistent with multisystem disorders that could be suggestive of an infection caused by any of the pathogens included in the panel of the tick-borne bacteria flow chip (TBFC) kit. Human DNA was used to spike positive controls came from cerebrospinal fluid (CSF) or biopsies from patients who tested negative to the pathogens included in the testing of the TBFC kit.

The TBFC is intended for the simultaneous qualitative detection of DNA from seven different genera of tick-borne bacteria, Anaplasma, Ehrlichia, Borrelia, Bartonella, Coxiella, Rickettsia, and Francisella, using a multiplex PCR followed by reverse dot blot automatic hybridization into a macroarray CHIP based on DNA-Flow Technology (hybriSpot). The kit offers the amplification of bacterial DNA by two multiplex polymerase chain reactions (PCRs) containing all primers for the specific amplification of the seven bacteria genera and two sets of primers for the amplification of two internal controls.

The scientists reported that the sensitivity of the TBFC was tested for each pathogen independently in the presence of human DNA. Despite human co-infections with tick-borne pathogens being rare, one of the strengths of the TBFC is that it can detect them. To prove that the TBFC detects co-infections, they included positive controls (103–104 plasmid copy/genome equivalents, PC/GE) for each pathogen. The results confirmed that the TBFC could detect all the pathogens simultaneously without compromising its sensitivity.

The TBFC platform offers four significant advantages. First, it is rapid and automatized, significantly shortening the time for the diagnosis of tick-borne pathogens. The TBFC kit gives results in 3.5 hours, while the in-house PCR-reverse line blot takes 8.5 hours for one pathogen. Second, it allows the simultaneous detection of multiple pathogens, which represents an excellent advantage for diseases that display similar symptoms early on. Third, the TBFC can analyze a wide variety of clinical samples with high sensitivity and specificity. Fourth, it is a valuable alternative to serology for early diagnosis.

The authors concluded that the TBFC kit is a rapid and highly sensitive and specific diagnostic tool, capable of simultaneously screening multiple bacterial pathogens. The study was published on October 22, 2019 in the journal Vector-Borne and Zoonotic Diseases.

Related Links:
Rutgers University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.